EVT.DE Evotec SE (XETRA) pre-market 03 Apr 2026: Q4 results due 08 Apr, catalyst ahead

EVT.DE stock opens pre-market on XETRA at €4.50, with investors focused on Evotec SE’s fourth-quarter and full-year 2025 report due 08 Apr 2026. The company trades well below its 50-day average of €5.42 and 200-day average of €6.03, making this release a near-term catalyst. Expect the call to address margin recovery, R&D pipeline progress and partner milestones that can move the stock in either direction.

EVT.DE stock: Pre-market snapshot and key data

Evotec SE (EVT.DE) trades on XETRA in Germany at €4.50. Today’s range is €4.33–€4.58, previous close €4.46 and volume 619,489 shares versus average 821,335. Market cap stands at €800,230,764 and shares outstanding are 177,710,585. EPS is -0.90 with a trailing PE of -5.00, reflecting negative earnings. These exact metrics frame the near-term risk-reward into earnings.

EVT.DE stock: Earnings calendar and what to watch

Evotec schedules Q4 and full-year 2025 results and a webcast for 08 Apr 2026. Analysts and investors will watch revenue guidance, partner program milestones and commentary on co-owned R&D assets. Management updates on collaborations with Bayer, Lilly, Pfizer and Novo Nordisk are a likely focus and can drive re-rating if tied to near-term payments or option exercises. The recent appointment of Dr. Ashiq H. Khan as Chief Commercial Officer adds a commercial lens. For the report, monitor contract revenue timing and any changes to unpartnered R&D spending that affect EBITDA and cash flow.

EVT.DE stock: Financials, valuation and Meyka grade

Evotec shows mixed fundamentals. Revenue per share is €4.26, book value per share €4.50, and cash per share €1.34. Price-to-sales is 1.06 and price-to-book is 0.99, below Healthcare sector PB of 6.39, implying the market prices a discount for profitability and growth uncertainty. Net margin and return metrics are negative, with ROE -18.11% and interest coverage -5.66, highlighting earnings pressure. Meyka AI rates EVT.DE with a score out of 100: 61.20 (Grade B) — HOLD. This grade factors S&P 500 and sector comparisons, financial growth, key metrics, forecasts and analyst consensus. The grade reflects fair valuation versus peers but flags profitability and cash-flow risks. These grades are not guarantees and we are not financial advisors.

EVT.DE stock: Technicals and trading setup

Technicals show a neutral-to-bearish bias. RSI is 42.33, MACD is -0.29 with a small positive histogram, and ADX at 33.15 indicates a strong trend. Bollinger middle band sits at €4.43 and the lower band at €3.78, which provides near-term support. The 50-day average is €5.42 and 200-day average €6.03; both are above spot price, signalling a downtrend since late 2025. Volume is below average today (relVolume 0.75), so watch for a volume surge on earnings. Traders may use €3.80 as a lower support and €5.40 as a first resistance level.

EVT.DE stock: Catalysts, risks and sector context

Primary catalysts: the 08 Apr 2026 earnings release, new partner payments, and clinical or M&A updates for co-owned assets. Management commentary on unpartnered R&D spend can sharply affect EBITDA and cash flow forecasts. Recent sector trends show Healthcare P/S around 3.34 and average PE around 29.1, which sets a high bar for re-rating. Key risks include continued negative margins, weak interest coverage, and revenue volatility tied to milestone timing. Evotec’s diversified partner base reduces single-counterparty risk, but execution on partnerships and internal R&D outcomes remains critical.

EVT.DE stock: Price scenarios and forecast outlook

Meyka AI’s forecast model projects short-term and longer-term paths. Monthly model: €3.93 (implied -12.67% vs €4.50). Quarterly model: €3.15 (implied -30.00%). Yearly model: €1.88 (implied -58.25%). Forecasts are model-based projections and not guarantees. Scenario price targets based on valuation and catalysts: bear €3.00 (down -33.33%), base €5.50 (up 22.22%), bull €8.50 (up 88.89%). These targets reflect revenue timing, milestone receipts, and pipeline de-risking rather than formal analyst consensus.

Final Thoughts

EVT.DE stock arrives at the April 8 earnings call as a catalyst stock with mixed signals. At €4.50, Evotec trades under its 50-day and 200-day averages, with a market cap of €800,230,764 and trailing EPS -0.90. The company has valuable partnerships and a broad R&D pipeline, but profitability and cash conversion remain weak. Meyka AI’s models show a range of outcomes: monthly €3.93 (-12.67%), quarterly €3.15 (-30.00%) and yearly €1.88 (-58.25%) versus the current price. Meyka’s scenario targets place a base case at €5.50, but risks could push the stock below €3.00 if milestones slip. Investors should weigh partner revenue visibility and management guidance from the webcast. As an AI-powered market analysis platform, Meyka AI flags the earnings call as the next decisive event for EVT.DE stock; traders should use clear stop-loss levels and confirm moves with volume and guidance details.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.